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Background
In Austria up to 25% of newly diagnosed HIV infected
patients present with less than 200 CD4 cell/mm3 and/
or AIDS (late presenters). Late diagnosis not only
adversely affects individual health and survival but may
also be associated with higher need for care, thus result-
ing in higher expenses for the healthcare system.
Purpose of the study
To assess the marginal costs of late presentation of
HIV-infection in Austria.
Methods
Direct costs incurred during follow-up, demographic
and clinical data were retrospectively collected for all
late presenters (=cases) and an age- and risk-group
matched cohort of controls (>350 CD4 cells/mm3 and
never AIDS at presentation) presenting at the HIV-unit
of the Medical University of Vienna between July 2006
and November 2008. Calculation of costs was based on
official standard reimbursement systems for in-patient
care, out-patient consultations, diagnostic procedures,
and drug prices paid by the social insurance company
or the hospital.
Results
24 cases and 27 controls were followed over a mean of
15 months. Cases and controls were well matched with
regards to age, gender, risk group, migrational back-
ground, and follow-up time (p=NS). Median overall
costs for late presenters incurred during the observation
period were nearly 5 times higher for cases than for
controls (21.166 vs. 4.329 Euros; p < 0,05). This differ-
ence was driven by higher costs for out-patient consul-
tations (p<0,005), in-patient care (p<0,0001), diagnostic
procedures (p< 0,02) and ART (p < 0,005). Costs for
non-antiretroviral drugs did not differ significantly
between the groups.
Conclusions
Late presentation of HIV-infection is associated with a
significant economic burden for the health system dur-
ing the initial period of care. Higher costs for ART due
to the immediate need for treatment account only for
part of these costs. Interventions promoting earlier diag-
nosis of HIV in Austria may therefore prove to be cost-
effective.
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